Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 109-120 , April 2010

Dyspepsia as an adverse effect of drugs

References 

  1. Holtmann G, Goebell H, Holtmann M, et al. Dyspepsia in healthy blood donors. Pattern of symptoms and association with Helicobacter pylori. Dig Dis Sci. 1994;39:1090–1098
  2. Straus WL, Ofman JJ, MacLean C, et al. Do NSAIDs cause dyspepsia? a meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol. 2002;97:1951–1958
  3. Aronson JK. Drug withdrawals because of adverse effects. In:  Aronson JK editors. Side effects of drugs. Oxford: Elsevier; 2008;p. xxxi–xxxvAnnual 30
  4. Meyler's side effects of drugs. 15th ed.. Oxford: Elsevier; 2006;
  5. Hallas J. Drug related hospital admissions in subspecialities of internal medicine. Dan Med Bull. 1996;43:141–155
  6. Bruppacher R, Gyr N, Fisch T. Abdominal pain, indigestion, anorexia, nausea and vomiting. Baillieres Clin Gastroenterol. 1988;2:275–292
  7. Shin YS, Lee YW, Choi YH, et al. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers. Pharmacoepidemiol Drug Saf. 2009;
  8. Nielsen OH. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1982;17:389–393
  9. Weiss AS, Markenson JA, Weiss MS, et al. Toxicity of D-penicillamine in rheumatoid arthritis. A report of 63 patients including two with aplastic anemia and one with the nephrotic syndrome. Am J Med. 1978;64:114–120
  10. Maclean CH, Morton SC, Ofman JJ, et al. How useful are unpublished data from the Food and Drug Administration in meta-analysis?. J Clin Epidemiol. 2003;56:44–51
  11. Hallas J, Bytzer P. Screening for drug related dyspepsia: an analysis of prescription symmetry. Eur J Gastroenterol Hepatol. 1998;10:27–32
  12. Bytzer P, Hallas J. Drug induced symptoms of functional dyspepsia and nausea. A symmetry analysis of one million prescriptions. Aliment Pharmacol Ther. 2000;14:1479–1484
  13. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7:478–484
  14. Tsiropoulos I, Andersen M, Hallas J. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf. 2009;18:483–491
  15. Paton A. Diseases of the alimentary system. Gastrointestinal reactions to drugs. Br Med J. 1976;2:1179–1180
  16. Price AB. Pathology of drug-associated gastrointestinal disease. Br J Clin Pharmacol. 2003;56:477–482
  17. Mantry P, Shah A, Sundaram U. Celecoxib associated esophagitis. Review of gastrointestinal side effects from Cox-2 inhibitors. J Clin Gastroenterol. 2003;37:61–63
  18. Hey H, Jørgensen F, Sørensen K, et al. Oesophageal transit of six commonly used tablets and capsules. BMJ. 1982;285:1717–1719
  19. Parfitt JR, Driman DK. Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol. 2007;38:527–536
  20. Eng J, Sabanathan S. Drug-induced esophagitis. Am J Gastroenterol. 1991;86:1127–1133
  21. Avidan B, Sonnenberg A, Schnell TG, et al. Risk factors for erosive reflux esophagitis: a case-control study. Am J Gastroenterol. 2001;96:41–46
  22. Walker J, Robinson J, Stewart J, et al. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin?. Interact Cardiovasc Thorac Surg. 2007;6:519–522
  23. Darji P, Vijayaraghavan R, Thiagarajan CM, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. Transplant Proc. 2008;40:2262–2267
  24. Eckstein RP, Symons P. Iron tablets cause histopathologically distinctive lesions in mucosal biopsies of the stomach and esophagus. Pathology. 1996;28:142–145
  25. Camilleri M. Diabetic gastroparesis. N Engl J Med. 2007;356:820–829
  26. Tack J. The difficult patient with gastroparesis. Best Pract Res Clin Gastroenterol. 2007;21:379–391
  27. Carbonell N, Pauwels A, Srfaty L, et al. Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Am J Gastroenterol. 2006;101:1211–1215
  28. Reimer C, Sondergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137:80–8787
  29. Mehta AJ, de Caestecker JS, Northfield TC. Effects of nifedipine and atenolol on gastro-oesophageal reflux. Eur J Gastroenterol Hepatol. 1993;5:627–629
  30. Petersen KU, Jaspersen D. Medication-induced oesophageal disorders. Expert Opin Drug Saf. 2003;2:495–507
  31. Ofman JJ, Maclean CH, Straus WL, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2003;49:508–518
  32. Henry DA, Johnston A, Dobson A, et al. Fatal peptic ulcer complications and the use of non-steroidal anti-inflammatory drugs, aspirin, and corticosteroids. Br Med J (Clin Res Ed). 1987;295:1227–1229
  33. Talley NJ, Evans JM, Fleming KC, et al. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci. 1995;40:1345–1350
  34. Larkai EN, Smith JL, Lidsky MD, et al. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol. 1989;11:158–162
  35. Vakil N, Rhew D, Soll A, et al. The cost-effectiveness of diagnostic testing strategies for Helicobacter pylori. Am J Gastroenterol. 2000;95:1691–1698
  36. Hansen JM, Hallas J, Lauritsen J, et al. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol. 1996;31:126–130
  37. Hollenz M, Stolte M, Leodolter A, et al. NSAID-associated dyspepsia and ulcers: a prospective cohort study in primary care. Dig Dis. 2006;24:189–194
  38. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non- steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350:975–979
  39. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14–22
  40. Van Groenendael JH, Markusse HM, Dijkmans BA, et al. The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol. 1996;15:450–456
  41. Gupta S, McQuaid K. Management of nonsteroidal, anti-inflammatory, drug-associated dyspepsia. Gastroenterology. 2005;129:1711–1719
  42. Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?. Ann Intern Med. 2000;132:134–143
  43. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520–15282
  44. Rabeneck L, Goldstein JL, Vu A, et al. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis. Am J Gastroenterol. 2005;100:1043–1050
  45. Lai KC, Chu KM, Hui WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005;118:1271–1278
  46. Spiegel BM, Farid M, Dulai GS, et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med. 2006;119:448;e27–36
  47. Watson DJ, Bolognese JA, Yu C, et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin. 2004;20:1899–1908
  48. Nandurkar S, Talley NJ, Xia HHX, et al. Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection. Arch Intern Med. 1998;158:1427–1433
  49. Chappel C, Neuman D, Thompson VJ, et al. Dyspeptic symptoms and sleep disturbance: a report from a large observational study in low-dose acetylsalicylic acid users. Gastroenterology. 2009;136(Suppl. 1):T1050
  50. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103:2465–2473
  51. Laheij RJ, van Rossum LG, Jansen JB, et al. Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial. Aliment Pharmacol Ther. 2003;18:109–115
  52. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–632
  53. Yocum DE, Furst DE, Bensen WG, et al. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford). 2004;43:992–999
  54. Lassen A, Hallas J, Schaffalitzky de Muckadell OB. Use of anti-secretory medication: a population-based cohort study. Aliment Pharmacol Ther. 2004;20:577–583
  55. Hunfeld NG, Geus WP, Kuipers EJ. Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther. 2007;25:39–46
  56. McColl KE, Gillen D. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology. 2009;137:20–22
  57. Davies M, Wilton LV, Shakir SA. Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England. Drug Saf. 2008;31:313–323
  58. Filippatos TD, Derdemezis CS, Gazi IF, et al. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008;31:53–65
  59. Tsertsvadze A, Yazdi F, Fink HA, et al. Oral sildenafil citrate (viagra) for erectile dysfunction: a systematic review and meta-analysis of harms. Urology. 2009;
  60. Hazell L, Cornelius V, Wilton LV, et al. The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients. BJU Int. 2009;103:506–514
  61. Nurnberg HG, Hensley PL, Heiman JR, et al. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008;300:395–404
  62. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016–1021
  63. McGowan B, Bennett K, Barry M, et al. The utilisation and expenditure of medicines for the prophylaxis and treatment of osteoporosis. Ir Med J. 2008;101:38–41
  64. Wallander MA, Johansson S, Ruigomez A, et al. Dyspepsia in general practice: incidence, risk factors, comorbidity and mortality. Fam Pract. 2007;24:403–411
  65. Barrera BA, Wilton L, Harris S, et al. Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England. Osteoporos Int. 2005;16:1989–1998

PII: S1521-6918(09)00160-7

doi: 10.1016/j.bpg.2009.11.006

Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 109-120 , April 2010

Article Tools

* Image Usage & Resolution